Apheresis Market

Executive Summary

Apheresis Market was valued at US $2.60 billion in 2021 and is projected to grow at 8.49% CAGR over the forecast period to reach US $4.25 billion by 2027. Apheresis Market represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $1.64 billion opportunity in 2027 over 2021.

Apheresis from Consainsights analyses the Apheresis Market in the Life Sciences industry over the forecast period to 2027.

Apheresis research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Apheresis segmentation includes Product, Procedure, Technology, Application, End User, Region and Geography.

Based on the Product, the Apheresis analysis covers Apheresis Disposables, Apheresis Devices.

In Product segment, Apheresis Disposables segment has highest cagr growth of 7.51%.

Based on the Procedure, the Apheresis analysis covers Automated Blood Collection (Donor Apheresis), Therapeutic Apheresis.

In Procedure segment, Automated Blood Collection (Donor Apheresis) segment has highest cagr growth of 7.51%.

Based on the Technology, the Apheresis analysis covers Centrifugation, Membrane Separation.

In Technology segment, Centrifugation segment has highest cagr growth of 7.51%.

Based on the Application, the Apheresis analysis covers Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, Photopheresis, Other Applications.

In Application segment, Plasmapheresis segment has highest cagr growth of 7.51%.

Based on the End User, the Apheresis analysis covers Blood Collection Centers & Blood Component Providers, Hospitals and Transfusion Centers, Other End Users.

In End User segment, Blood Collection Centers & Blood Component Providers segment has highest cagr growth of 7.51%.

Based on the Region, the Apheresis analysis covers North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

In Region segment, North America segment has highest cagr growth of 7.51%.

Based on the region, the Apheresis analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Terumo BCT, Inc., Fresenius Se & Co. KGaA, Haemonetics Corporation, Baxter International Inc., Asahi Kasei Medical Co. Ltd. (A Subsidiary of Asahi Kasei Corporation), B. Braun Melsungen AG, Cerus Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., Nikkiso Co., Ltd., Macopharma SA, Miltenyi Biotec, Otsuka Holdings Co., Ltd., Medica Spa, Mallinckrodt Plc, Medicap Clinic GmbH, LMB Technologie GmbH, Bioelettronica Srl, Infomed, Cytosorbents Corporation, Toray Medical Co., Ltd. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Apheresis Disposables segment has the highest revenue of US $1.47 billion and is expected to grow at CAGR of 7.51% by 2027 Apheresis Disposables segment has highest cagr growth of 7.51%.

Apheresis Disposables

Apheresis Disposables segment was valued at US $1.25 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $2.39 billion by 2027. Apheresis Disposables segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.92 billion opportunity in 2027 over 2021.

Apheresis Devices

Apheresis Devices segment was valued at US $0.97 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1.86 billion by 2027. Apheresis Devices segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.72 billion opportunity in 2027 over 2021.

Procedure

Introduction

In 2021, Automated Blood Collection (Donor Apheresis) segment has the highest revenue of US $2.15 billion and is expected to grow at CAGR of 7.51% by 2027 Automated Blood Collection (Donor Apheresis) segment has highest cagr growth of 7.51%.

Automated Blood Collection (Donor Apheresis)

Automated Blood Collection (Donor Apheresis) segment was valued at US $1.83 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $3.50 billion by 2027. Automated Blood Collection (Donor Apheresis) segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.36 billion opportunity in 2027 over 2021.

Therapeutic Apheresis

Therapeutic Apheresis segment was valued at US $0.39 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.74 billion by 2027. Therapeutic Apheresis segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.29 billion opportunity in 2027 over 2021.

Technology

Introduction

In 2021, Centrifugation segment has the highest revenue of US $2.23 billion and is expected to grow at CAGR of 7.51% by 2027 Centrifugation segment has highest cagr growth of 7.51%.

Centrifugation

Centrifugation segment was valued at US $1.89 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $3.63 billion by 2027. Centrifugation segment represented US $0.34 billion opportunity over 2019-2021 and estimated to create US $1.41 billion opportunity in 2027 over 2021.

Membrane Separation

Membrane Separation segment was valued at US $0.32 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.61 billion by 2027. Membrane Separation segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.24 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Plasmapheresis segment has the highest revenue of US $1.00 billion and is expected to grow at CAGR of 7.51% by 2027 Plasmapheresis segment has highest cagr growth of 7.51%.

Plasmapheresis

Plasmapheresis segment was valued at US $0.85 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1.63 billion by 2027. Plasmapheresis segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.63 billion opportunity in 2027 over 2021.

Plateletpheresis

Plateletpheresis segment was valued at US $0.54 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1.04 billion by 2027. Plateletpheresis segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.40 billion opportunity in 2027 over 2021.

Erythrocytapheresis

Erythrocytapheresis segment was valued at US $0.35 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.67 billion by 2027. Erythrocytapheresis segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.26 billion opportunity in 2027 over 2021.

Leukapheresis

Leukapheresis segment was valued at US $0.26 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.50 billion by 2027. Leukapheresis segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

Photopheresis

Photopheresis segment was valued at US $0.12 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.22 billion by 2027. Photopheresis segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.09 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.10 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.18 billion by 2027. Other Applications segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Blood Collection Centers & Blood Component Providers segment has the highest revenue of US $1.79 billion and is expected to grow at CAGR of 7.51% by 2027 Blood Collection Centers & Blood Component Providers segment has highest cagr growth of 7.51%.

Blood Collection Centers & Blood Component Providers

Blood Collection Centers & Blood Component Providers segment was valued at US $1.52 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $2.91 billion by 2027. Blood Collection Centers & Blood Component Providers segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.13 billion opportunity in 2027 over 2021.

Hospitals and Transfusion Centers

Hospitals and Transfusion Centers segment was valued at US $0.54 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1.04 billion by 2027. Hospitals and Transfusion Centers segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.40 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $0.15 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.29 billion by 2027. Other End Users segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.11 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $1.12 billion and is expected to grow at CAGR of 7.51% by 2027 North America segment has highest cagr growth of 7.51%.

North America

North America segment was valued at US $0.96 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1.83 billion by 2027. North America segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.71 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.55 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $1.06 billion by 2027. Europe segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.41 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.33 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.64 billion by 2027. Asia Pacific segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.25 billion opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $0.33 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.64 billion by 2027. Latin America segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.25 billion opportunity in 2027 over 2021.

Middle East & Africa

Middle East & Africa segment was valued at US $0.04 billion in 2019 and is projected to grow at 7.51% CAGR over the forecast period to reach US $0.07 billion by 2027. Middle East & Africa segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.